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REGULAR ARTICLE
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Key Points
• Pediatric ALL relapses
after allogeneic stem
cell transplantation
display highly diverse,
dynamic and patient-
individual genetic
lesions.
•Nine of 10 relapsing
pediatric transplant
recipients present with
genetic alterations for
which novel targeted
therapies are available.
Survival of patients with pediatric acute lymphoblastic leukemia (ALL) after allogeneic
hematopoietic stem cell transplantation (allo-SCT) is mainly compromised by leukemia
relapse, carrying dismal prognosis. As novel individualized therapeutic approaches are
urgently needed, we performed whole-exome sequencing of leukemic blasts of 10 children
with post–allo-SCT relapses with the aim of thoroughly characterizing the mutational
landscape and identifying druggable mutations. We found that post–allo-SCT ALL relapses
display highly diverse and mostly patient-individual genetic lesions. Moreover, mutational
cluster analysis showed substantial clonal dynamics during leukemia progression from
initial diagnosis to relapse after allo-SCT. Only very few alterations stayed constant over
time. This dynamic clonality was exempliﬁed by the detection of thiopurine resistance-
mediating mutations in the nucleotidase NT5C2 in 3 patients’ ﬁrst relapses, which
disappeared in the post–allo-SCT relapses on relief of selective pressure of maintenance
chemotherapy. Moreover, we identiﬁed TP53mutations in 4 of 10 patients after allo-SCT,
reﬂecting acquired chemoresistance associated with selective pressure of prior
antineoplastic treatment. Finally, in 9 of 10 children’s post–allo-SCT relapse, we found
alterations in genes for which targeted therapies with novel agents are readily available.
We could show eﬃcient targeting of leukemic blasts by APR-246 in 2 patients carrying
TP53 mutations. Our ﬁndings shed light on the genetic basis of post–allo-SCT relapse
and may pave the way for unraveling novel therapeutic strategies in this challenging
situation.
Submitted 19 February 2019; accepted 8 July 2019. DOI 10.1182/
bloodadvances.2019000051.
*J.I.H., S.G., and M.K. contributed equally to this work.
For original data not provided in the supplemental Data, please contact jessica.hoell@
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The full-text version of this article contains a data supplement.
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Introduction
Acute lymphoblastic leukemia (ALL) represents the most prevalent
pediatric cancer. Through the collaborative effort of large random-
ized multiinstitutional trials, approximately 90% of all pediatric
patients with ALL survive for at least 5 years.1 Survival rates of
patients with ALL who respond poorly to first-line treatment or
who relapse are much less favorable. Thus, these children are
eligible for allogeneic hematopoietic stem cell transplantation
(allo-SCT) and display survival rates of 70% to 75% if allo-SCT
is performed in complete remission.2,3
Although nonrelapse mortality could substantially be reduced via
optimization of donor selection and supportive care, post–allo-SCT
relapses still represent the major cause of treatment failure.4 A
durable remission providing a realistic perspective for definitive cure
is only rarely achieved, in particular when relapses occur early.5,6
Standard protocols for this situation do not exist, and treatment
options in these heavily pretreated children are limited, in part
because of cumulative toxicity. Thus, treatment remains a therapeu-
tic challenge, and administered therapy represents individual case-
based decisions, including immunotherapeutic approaches such
as the CD19/CD3-bispecific antibody blinatumomab,7,8 the CD22-
directed immunotoxin inotuzumab ozogamicin, or CD19-directed
CAR-T cells.9,10
Second SCT has proven, among other options such as the above-
mentioned CAR-T cells, to represent a curative treatment approach
to some of these children with disease-free survival rates approximating
30% after 2 years.5,11 However, before proceeding to second SCT,
complete morphologic remission or, even more challenging, a very
low or negative minimal residual disease level should be achieved.5
Thus, novel individualized therapeutic approaches are urgently
needed to achieve this goal. Because post–allo-SCT relapses
escaped the combined chemotherapeutic and immunologic attack,
they are presumed to display distinct genetic alterations compared
with those ALL relapses after conventional chemotherapy.12
Two recent studies evaluated the landscape of genomic alterations
in large cohorts of patients with pediatric cancer.13,14 In addition to
defining distinct mutational patterns, these analyses revealed
that nearly 50% of pediatric neoplasms harbor a potentially
druggable genetic event. Moreover, several investigators have
analyzed mutational profiles in pediatric ALLs focusing on initial
disease and first relapses.15-21 There remains, however, a lack
of information on genetic alterations in pediatric post–allo-SCT
relapses.
Here, it is of particular importance that the bone marrow comprises
recipient-originating leukemic blasts and donor hematopoietic
cells. Thus, to faithfully identify genetic lesions specific to the
post–allo-SCT relapse, both donor and recipient genetic back-
grounds must be considered (Figure 1A).
To address the urgent clinical need for identification of novel
patient-individualized treatment approaches, we here performed
whole-exome sequencing of leukemic blasts of 10 pediatric trans-
plant recipients with post–allo-SCT relapses, and reveal substantial
individuality and clonal dynamics of genetic alterations, selective
pressure, and a high prevalence of mutations in such genes, for
which nonstandard therapies with novel, approved agents are
readily available.
Patients, materials, and methods
Patient samples
All patients were enrolled in multicenter pediatric ALL trials. The
treatment studies and the concomitant research were all approved
by the respective institutional review boards, and informed consent
was obtained from all parents.
Exome library preparation and NGS
Nucleid acids were extracted using AllPrep DNA/RNA Mini Kit
(Qiagen, Hilden, Germany). Exome library preparation was performed
as detailed in Hoell et al.22 Two times 100 bp sequencing with a 6-bp
index read was performed using the TruSeqTM SBS Kit v51UTR on
the HiSeq 2500 (Illumina, San Diego, CA). All sequencing data are
available on request.
Sanger sequencing
Selected single nucleotide variants (SNVs) from exome sequenc-
ing (NT5C2: 514, 735; TP53: 514, 590, 660) were validated by
Sanger sequencing (primer sequences in supplemental Methods)
and were confirmed in all cases. See the supplemental Methods for
details on the amplicon sequencing.
APR-246 sensitivity testing
Sensitivities of patient/xenograft leukemia samples to APR-246
(kindly provided by Aprea Therapeutics, Stockholm, Sweden)
were assessed after incubation of ALL cells with increasing
concentrations analyzing cell death by flow cytometry according
to forward- and side-scatter criteria in triplicate measurements.
Bioinformatic analysis
Fastq files were generated using BcltoFastq 1.8.4 (Illumina). BWA
version 0.6.1-r10423 with default parameters to align sequence
data to the human reference genome (GRCh37). Conversion
steps were carried out using Samtools,24 followed by removal of
duplicate reads.25,26 Local realignment around indels, SNV-calling,
annotation, and recalibration was facilitated by GATK.27 HapMap,
OmniArray, and dbSNP135 datasets provided by The Broad Institute
were used for recalibration. Resulting variant calls were annotated by
Variant Effect Predictor,28 using the Ensembl database (v70) and
imported into an in-house MySQL database to facilitate auto-
matic and manual annotation, reconciliation, and data analysis by
complex database queries. Loss of function prediction scores for
PolyPhen229 and SIFT30 were extracted from the same Ensemble
release.
To identify clones that follow a common clonal pattern during
oncogenome progression, we applied a density-based clustering
approach31 to the log-scaled frequencies of the somatic variants.
Computing the Euclidean distance matrix on the logarithmic scaled
frequencies allows the mitigation of the higher possible variance
that occurs in high-frequency mutations compared with low-frequency
mutations, which influences the Euclidian distances disproportionally.
Frequencies were extracted using samtools from the alignments,
using bases that exceeded the base quality of 13. Variants with
a frequency of 0.0 were set to an artificial minimum of 1024 for
this scaling, 3 magnitudes smaller than the average read depth
observed for the somatic mutations (79.23). We used the dbscan
R package for the clustering.32 Alluvial diagrams of alternate allele
fractions were generated using ggalluvial R package. Please see
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the supplemental Methods for details on the deep sequencing
analysis and the computation of the oncogenomes.
Results
Cohort of 10 patients relapsing with ALL after SCT
All 10 patients were enrolled in multicenter pediatric ALL trials
(ALL-BFM, CoALL, ALL-REZ BFM, ALL-SCT BFM 2003,
TCRalpha/b-Haplo2010 trial). Mean age at first diagnosis was
4.6 years (range, 0.3-10.2 years), mean time from first diagnosis to
relapse before allo-SCT was 2.2 years (range, 1.1-3.4 years), and
mean time from initial diagnosis to post–allo-SCT relapse was
3.1 years (range, 0.8-5.1 years). Time from SCT to post–allo-SCT
relapse was short (mean, 0.7 years; range, 0.2-1.7 years). Seven
patients had received a matched-unrelated donor transplant, in
2 cases an HLA-identical sibling served as donor, and 1 patient
was transplanted from his HLA-haploidentical mother (Table 1;
supplemental Table 1). In 9 of 10 patients, signs of neither
clinically significant acute nor chronic GvHD were reported
to the study center (information missing for 1 patient). Because
of the lack of standardized protocols, treatment after the
post–allo-SCT relapse varied considerably and ranged from
palliative care to second allo-SCT. At the time of this analysis,
only 2 patients were still alive, reflecting the dismal prognosis of
post–allo-SCT relapses.
Addressing the 2-germline challenge to receive
leukemia-specific SNVs after SCT
To address the question of how pediatric pre– and post–allo-SCT
ALL relapses differ on a genetic level, we performed WES of 5
samples per patient (Figure 1A; supplemental Tables 2 and 3).
Because post–allo-SCT relapses usually occur in a situation of
hematopoietic chimerism, 2 genetic germline backgrounds (donor
and recipient) were subtracted to uncover mutations specific to
the post–allo-SCT relapse. To receive a comprehensive picture,
we combined the outputs of 2 SNV callers, namely, MuTect33 and
VarScan2,34 as prior reports had revealed that this approach
provides a more complete overview of the oncogenomes in acute
leukemia.35
To enable comparative analyses, we defined the following 3
“oncogenomes” (OGs): OG1 (initial leukemia, defined as SNVs
in INIT minus those in REMI), OG2 (first relapse, defined as
RLPS minus REMI), and OG3 (post–allo-SCT relapse, defined
as OG3 5 [TRLPS-REMI]ᴖ[TRLPS-TREMI]).
All SNVs from the first 4 patients in our series (514, 590, 660,
685) were validated in silico by manually checking all identified
SNVs via assessment of sufficient sequencing depths in all
patient samples and verifying B allele frequencies (BAF) in the
mutated vs nonmutated samples with complete concordance
in all instances.
Treatment:
Chemo ?
Treatment:
Chemo ?
+ SCT
Experimental
treatment
OG1: 1 - 2
Patient hematop. Donor hematop. Blasts
OG2: 3 - 2 OG3: 5 - 4 - 2
Initial Dx (1)
INIT REMI RLPS TRLPSTREMI
Remission (2)
allo SCT
Relapse (3)
Relapse
post SCT (5)
Full donor
chimerism (4)
A
UPN
107
202
316
318
337
514
590
660
685
735
Median
OG1
4
n/a
5
15
16
12
354
10
28
n/a
13.5
OG2
n/a
44
1190
136
33
1221
27
45
50
83
50.0
OG3
32
57
39
27
62
667
22
54
89
826
55.5
B
C
UPN
OG2 MAD2L1
POLR1A, POLR3A,
POLD1,POLD4
POLR2A, POLR3E
BRCA2, FANCC,
POLK
BRIP1, FANCM,
POLD1, POLQ,
POLR3B, POLR3H
OG
OG2
OG3
OG1
OG3
316
514
514
590
735
gene
D p = 0.005
0.1
OG1 OG2
somatic mutations per megabase
OG3
0.3
1
3.2
10
Figure 1. Large oncogenomes are characterized
by acquired mutations in DNA repair genes. (A)
Experimental setup including oncogenomes (OG).
For patients 202 and 735, no material of the initial
leukemia (INIT) was available; patient 107 did not
relapse before allo-SCT. (B) Sizes of the individual
oncogenomes. (C) Mutational loads across the onco-
genomes. The increase from OG1 vs OG2/OG3 was
statistically significant (P 5 .005). (D) Mutations in
DNA polymerase/repair genes explaining the large
oncogenomes. n/a, not available; REMI, first re-
mission; RLPS, first relapse; TREMI, remission after
allo-SCT; TRLPS, relapse after allo-SCT; UPN,
unique patient identifier.
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Large oncogenomes are characterized by acquired
mutations in DNA repair genes
Median numbers of leukemia-specific SNVs in OG1-3 were 13.5,
50, and 55.5, respectively. As can be seen in Figure 1B, SNV
counts of individual oncogenomes varied substantially, but proved
usually below 200. There was, however, 1 outlier in OG1 (590), 2 in
OG2 (316, 514), and 2 in OG3 (514, 735; supplemental Table 4 for
a full gene list).
Next, we investigated the 4 patients, who had unexpectedly large
OGs. We found that all these oncogenomes carried newly acquired
somatic SNVs in either DNA polymerases or DNA repair/Fanconi
anemia genes, and all SNVs were exclusive to the respective large
oncogenomes (Figure 1C; supplemental Table 5). Of note, no DNA
polymerase/DNA repair gene mutations were detected in any of the
other oncogenomes.
Looking at the therapy that these 4 patients received, there were no
specific treatment elements that could be correlated with the
occurrence of DNA polymerase/DNA repair gene mutations and
high mutational load (supplemental Table 1).
Oncogenomes are exclusive to individual patients and
relapse states
We detected a median of 0.18 mutations per megabase in OG1,
0.67 mutations per megabase in OG2, and 0.74 mutations per
megabase in OG3. The increase in mutational load between initial
leukemia and the relapses was statistically significant (P 5 .005;
Figure 1D). Mutational load was comparable between OG2 and
OG3; however, there was a profound shift on gene level, as most
affected genes differed between OG2 and OG3 (Figure 2A).
Next, we analyzed which mutated genes were recurrently affected.
In OG1, 5 genes carried SNVs in at least 2 patients (TTN, IGSF3,
NOTCH1, CTBP2, NRAS), with NOTCH1 exhibiting SNVs in the
2 T-ALL patients (660, 685). In the case of OG2, 158 genes
were recurrently mutated in at least 2 patients, of which 72 were
only affected in the 2 patients (316, 514), who presented with
exceptionally large oncogenomes. A total of 7 genes were affected
3 times (Figure 2B).
In OG3, 116 genes had SNVs in at least 2 patients, of which 58
genes were affected in both patients with large oncogenomes
(514, 735) and 8 genes were affected in at least 2 patients
excluding these 2 patients (Figure 2C; supplemental Tables 6
and 7).
Looking longitudinally at those 7 patients, from whom all 3 leukemia
samples were available, only the minority of SNVs were recurrently
detected in all leukemia states (Figure 2A). These 7 patients had
a mean number of 7.1 genes (median, 6 genes; total, 50 genes in
7 patients) forming the core mutational sets in all 3 leukemias
(supplemental Table 8). Of these, a mean number of 2 genes
(median was also 2 genes) were known cancer genes. The only
recurrent gene in the list of 50 genes was NOTCH1 in the T-cell
leukemias.
In some cases (patients 316, 318, 660, 685), these “core genes“
likely represented driving leukemic mutations (including BCL6,
ERG, KRAS, NOTCH1, NRAS). In the 3 other patients (337,
514, 590), the situation was less clear, as the genes found have
so far not been described as classic leukemic mutations, open-
ing the possibility that they represent bystander mutations of the
dominant clone.
Thus, we identified profound clonal dynamics in the mutational
landscapes, not only between initial diagnosis and relapse, but
likewise between pre– and post–allo-SCT relapses.
Mutational clusters show substantial leukemic clonal
dynamics from initial diagnosis across all relapses
As only the minority of affected genes overlapped between the 3
oncogenomes, which hinted at substantial leukemic clonal dynam-
ics, we wished to assess leukemic evolution over time. To achieve
this, we defined mutational clusters, which consisted of genes with
similar mutational frequencies. We focused on those 7 patients
(316, 318, 337, 514, 590, 660, 685) for which all 3 leukemias were
available. Only the minority of patients (n 5 3) carried clusters,
which were present (BAF $ 0.1) without relevant changes in
frequency across all 3 leukemias (supplemental Figure 1). The
majority of patients carried at least 1 mutational cluster, which
was present only in OG1, OG2, or OG3. In addition, 6 patients
had clusters, which were first present in OG2 and continued to
be detectable (at similar BAF levels) in OG3. Figure 3 shows
pronounced dynamic clonal outgrowth of all mutational clusters
(ie, clones) in the left column. The middle and right column show
that this dynamic clonal behavior also affects pathogenetically
relevant genes, thus underscoring that the most recent leukemia
Table 1. Clinical characteristics of the 10 analyzed patients
UPN 107 202 316 318 337 514 590 660 685 735
Sex F F M M M M F M F M
Age at first disease, y 0.3 5.7 1.0 5.3 2.8 2.5 7.3 5.1 5.7 10.2
Immunophenotype cALL cALL cALL cALL cALL cALL cALL cort. T pro-T pB-ALL
Age at relapse, y n/a 7.5 3.3 7.7 5.9 5.0 10.7 6.4 6.8 12.3
Time to relapse, y n/a 1.8 2.3 2.4 3.1 2.5 3.4 1.3 1.1 2.1
Age at SCT, y 0.8 8.1 3.9 8.0 6.3 5.5 11.2 6.7 7.0 12.8
MRD before SCT ,1 3 1024 ,1 3 1023-1 3 1024 1 3 1026 1 3 1024 ,1 3 1024 ,1 3 1024 ,1 3 1025 ,1 3 1024 1 3 1023-1 3 1024 ,1 3 1024
Time to relapse after SCT, y 0.3 0.7 0.4 1.7 1.2 0.3 1.2 0.6 0.2 0.2
Survival status Alive Dead Dead Alive Dead Dead Dead Dead Dead Dead
cort., cortical; F, female; M, male; MRD, minimal residual disease; SCT, stem cell transplantation; UPN, unique patient identifier.
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0
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0
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47
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1
9
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514
OG2
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1
332
3
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1
0
8
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OG2 OG1
OG3
1
3
41
6
0 7
31
660
OG2 OG1
OG3
3
16
76
9
0 4
34
685
OG2
OG1
OG3
0
1
29
4
0 6
1180
316
OG2OG1
OG3
n.d.
2
2
n.d.
30
n.d.
n.d.
107
OG2A
CTBP2
10
7
20
2
31
6
31
8
33
7
51
4
5
9
0
6
6
0
6
85
73
5
OG2
IKZF1
MUC16
NOTCH1
NRAS
FAM160A2
NT5C2
B
OBSCN
ACAP1
WWC3
ABCA8
CLASP1
TP53
FLT4
TTN
COL6A1
NRAS
ZDBF2
10
7
20
2
31
6
31
8
33
7
51
4
5
9
0
6
6
0
6
85
73
5
OG3C
OG1
n.d.
n.d.
34
n.d.
n.d. 23
21
202
OG2
OG3
Figure 2. Oncogenomes are exclusive to individual patients and relapse states. (A) Mutational spectra on SNV level in OG1, OG2, and OG3. (B) Recurrently mutated
genes ($3 patients) in OG2 (also see supplemental Table 6). UPNs as earlier. (C) Recurrently mutated genes ($3 patients) in OG3 (also see supplemental Table 7). n.d.,
not done.
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always has to be sequenced for a full picture of the mutational
picture. Specifically, in most patients, at least 1 mutational cluster
containing either known cancer and/or druggable genes newly
arose in the post–allo-SCT relapse. Thus, as the mutational clusters
containing cancer genes prove as dynamic as those with other
genes, this hints at different oncogenic drivers for each leukemic
state (Figure 3).
In addition, we analyzed which T-cell receptor (TCR) and immuno-
globulin gene rearrangements were identified by minimal residual
disease marker screening in the patient’s individual leukemia genomes
before and after SCT, respectively. As shown in supplemental Table 9,
we found gains (n 5 3) or losses (n 5 1) of immunoglobulin
H/TCR-based minimal residual disease markers in 4 of 7 patients’
ALL relapses after allo-SCT.
Disappearance of NT5C2 mutations in
post–allo-SCT relapses
Our overall hypothesis was that the selective pressure of admin-
istered therapies strongly affects the molecular makeup of leukemic
blasts. Accordingly, we focused on the gene NT5C2, in which
activating mutations were shown to drive 6-mercaptopurine (6-MP)
and 6-thioguanine (6-TG) resistance.18,19 As our patients had only
been treated with those nucleoside analogs during maintenance
therapy (and also in blocks during the intensive phases of
chemotherapy) before allo-SCT, tracking of NT5C2 alterations
gave us a unique opportunity to evaluate the dynamic clonal
outgrowth of leukemic blasts. In OG1, no NT5C2 SNVs were
detected. However, we found a total of 4 nonsynonymously coding
SNVs in NT5C2 (Figure 4A; supplemental Table 10) in the OG2 of
3 of 10 of our patients. One of the SNVs, which was detected in
2 patients (R367Q), is well-known in its pronounced enzyme-
activating properties.18,19 The other 2 SNVs (K26E, D113N) have
so far not been described. Notably, all NT5C2 SNVs that were
detected in OG2 disappeared again in OG3 once selection pressure
of maintenance chemotherapy employing nucleoside analogs had
been withdrawn (Figure 4A). Only 1 very small subclone persisted in
the post–allo-SCT relapse (clone size, 0.28%, patient 514/D113N),
whereas the other cases proved negative with a high sensitivity of
0.1% to 0.2%, as determined by amplicon sequencing.
High frequency of TP53 mutations in
post–allo-SCT relapses
Looking more specifically at recurrently mutated genes, we detected
TP53 mutations in 5 of 10 patients (Figure 4B; supplemental
Table 11) and, importantly, in 4 of 5 cases, at least 1 TP53mutation
was present in the post–allo-SCT relapse. One patient (590) had
previously undiagnosed Li-Fraumeni syndrome. In the other 4 patients,
1 patient (514) had 1 unique SNV each in OG2 as well as OG3,
1 patient (735) only in OG2, and 2 patients had TP53 mutations
only present in their OG3s (660, 685). One patient (685) acquired
3 different mutations in OG3. All identified TP53 mutations were
predicted to be functionally relevant and were previously described
in cancer and/or Li Fraumeni families (http://p53.iarc.fr/).
As with the NT5C2 mutations, the subclonal presence vs absence
of the TP53 SNVs in preceding and subsequent samples was
additionally analyzed via amplicon-based deep sequencing; in 3
of 7 analyzed cases a minor subclone was detected by deep
sequencing (Figure 4B) in the prior relapse sample. Of particular
interest, TP53-mutated minor subclones of 0.09% and 0.10%
were found in the pre–allo-SCT relapse in 2 of 3 patients (514/
R181H and 660/R248P), which then gave rise to clonal mutations
in the post–allo-SCT leukemia. Time to post–allo-relapse could not
be correlated to the presence of very low level TP53 mutations in
the relapse preceding SCT; however, time to relapse was extremely
short in all patients relapsing with TP53 mutations, highlighting the
high aggressiveness of this leukemia (median time to post–allo-SCT
relapse, 0.6 vs 0.2 years).
Cancer genes are recurrently mutated in OG3 and
present in the core set of patient-individual mutations
Next, we analyzed which cancer-associated genes in addition to
TP53 were mutated in the oncogenomes. Except for patient
514 in OG1, all other 26 oncogenomes showed mutations in at
least 1 cancer-related gene (as determined by the cancer gene census;
Figure 5A). Twenty-nine mutations were found in all OG1 combined,
and 67 mutations in all OG2 combined. Regarding those mutated
genes representing the core set of genetic alteration present in all
leukemia states of an individual patient, we found at least 1 cancer-
associated gene in 8 of 10 patients (supplemental Table 12).
Looking in more detail into OG3, 65 mutations were identified
across all 10 post–allo-SCT relapses (Figure 5B).
Genetic lesions in 9 of 10 post–allo-SCT relapses can
be targeted by nonstandard therapeutic agents
Next, based on a drug-target relationship recently employed by the
German INFORM consortium,36 we searched for genetic alterations
targeted directly (a certain gene) or indirectly (a certain pathway) by
novel therapeutic agents already approved, and thus readily avail-
able in this clinically difficult situation of post–allo-SCT relapse.
Of particular note, 9 of 10 patients exhibited SNVs in genes and/or
pathways, for which at least 1 additional targeted therapy is
available (Figure 5C; supplemental Table 13). Those therapeu-
tic agents comprised small-molecule inhibitors, tyrosine kinase
inhibitors, and antibodies such as Cabozantinib, Canakinumab,
Dasatinib, Erlotinib, Ibrutinib, Pazopanib, Olaparib, Sunitinib,
and Trametinib. In addition, CDKN2A/B deletions as well as
TP53 mutations are also targetable (Figure 5C).
Mutational cluster analysis containing druggable genes yet
again revealed clusters, which proved highly variable, both
between patients and between leukemic states of single patients
(Figure 3).
As already described here, all TP53 mutations identified in
post–allo-SCT relapses affect the DNA-binding domain. Emerging
data indicate that ALL cell lines and primary ALL samples harboring
this type of TP53 alteration are particularly sensitive to the small
molecule APR-246, which induces restoration of p53 wild-type
conformation in vitro and in vivo.37-41 Thus, we performed in vitro
drug sensitivity assays with leukemic blasts from the 2 patients 514
(R181H) and 660 (R248P) from the respective post–allo-SCT
relapses. We could show sensitivity of blasts against APR-246 in
both cases (Figure 5D).
Discussion
Our study provides the first comprehensive analysis of the exomic
mutational landscape of pediatric post–allo-SCT relapses, including
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Figure 3. Mutational clusters show profound clonal dynamics. Shown are the 7 patients for whom information on all 3 oncogenomes was available (A: 316, 318, 337,
514; B: 590, 660, 685). Different mutational patterns can be observed, both within as well as across the patients. Individual clusters are indicated and marked in different colors.
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amplicon-based deep sequencing of NT5C2 and TP53 mutations
for an in depth-analysis of their clonal dynamics. The main findings
include high individuality and profoundly dynamic outgrowth of
individual mutations.
The spectrum of somatic mutations in our patient cohort proved
highly diverse and patient-specific, reflecting a mostly private set
of specific genetic alterations found in each of the 10 children.
Moreover, we identified profoundly dynamic mutational spectra
in individual patient’s leukemias over time (Figure 3). Although
we cannot exclude subclonal contributions, which fell below
our threshold of detection, the observed individuality of the oncoge-
nomes was not unexpected, as childhood ALL represents a genet-
ically heterogeneous disease. On a molecular level, the pathogenesis
of pediatric ALL is primarily determined by the lineage origin (B-cell
or T-cell) and the presence of subtype-defining chromosomal trans-
locations and specific somatic aberrations,42,43 and, thus, requires
individual sequencing of the most recent leukemic samples.
As previously described in both relapsed pediatric B- and T-cell
leukemias,44-46 specific changes of relapsed leukemias include
activating mutations in the gene NT5C2, which result in increased
B all genes
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Figure 3. (Continued) The y-axis shows the percentages of sequenced reads in a particular cluster, the changing situations over time (OG1, OG2, OG3 are depicted on the
x-axis). The left column shows all mutational clusters in each patient, the middle column only those mutational clusters carrying cancer genes and the right column only those
carrying alterations in potentially druggable genes.
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Figure 4. Clonal dynamics and selective pressure of NT5C2
and TP53 mutations. (A) Graphs indicate the variant allele
frequencies in the SNVs in NT5C2 as detected by whole-exome
sequencing (supplemental Table 9). Patient identifiers (UPN) as
well as amino acid exchanges are indicated. Below each graph,
the results of the amplicon sequencing (AS) are indicated. (B)
SNVs detected in TP53 (also supplemental Table 10). The Li-
Fraumeni patient (590) is not shown.
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Figure 5. Mutations in cancer genes and targetable genetic lesions in the post–allo-SCT relapses. (A) Mutated cancer genes across all patients and oncogenomes.
(B) Details on those cancer genes, which were mutated in at least 2 patients. UPNs as earlier. (C) Targetable genes carrying mutations in the OG3 of the respective patients,
with possible therapeutic options indicated. SNVs are indicated in red, copy number losses in orange, hypermutated oncogenomes (defined by $200 SNVs) in blue. (D)
Sensitivity testing of patient cells/patient-derived xenografts against APR-246 in different concentrations (1-5-10-100 micro molar). neg. ctrl., negative control (primograft X116;
TP53 wild-type); pos. ctrl., positive control (TP53 mutant primograft X172 carrying 2 TP53 mutations on different alleles).
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nucleotidase activity, conferring resistance to chemotherapy with
6-mercaptopurine and 6-thioguanine.19 We identified 1 known
(R367Q) mutation in our study, as well as 2 not previously
described mutations (K26E, D113N) in a total of 3 patients
(prevalence 33%). Of interest, these mutations disappeared in
the post–allo-SCT relapse, as confirmed by amplicon sequencing
in all affected children once selection pressure of maintenance
therapy (and blocks during the intensive phase of treatment) had
been lifted. This finding demonstrating substantial clonal outgrowth
and adaptivity is in line with the very recent observations that
NT5C2 mutations while conferring resistance to maintenance
chemotherapy come at the cost of impaired leukemia cell growth
and leukemia-initiating cell activity, and thus decrease the fitness of
the leukemic blasts.47
In our study, we identify TP53 mutations in 4 of 10 patients with
post–allo-SCT relapse, which appears significantly more prevalent
than in a previous study reporting TP53 alterations in 30 (11%) of
265 children with first ALL relapse (Fisher’s exact test P5 .02).48-51
TP53 mutations are known to confer poor prognosis and are more
common in relapsed pediatric ALL compared with initial disease52;
however, the substantially increased frequency of TP53 alterations
observed in our study for the post–allo-SCT relapses compared
with the setting of first pre–allo-SCT relapses reflects selection
induced by highly intensive treatment. This fits well with the
recent observation that genotoxic stresses promote the clonal
expansion of hematopoietic stem cells expressing mutant TP53,
increasing the possibility of acquiring additional genetic and/or
epigenetic changes.53
All TP53 mutations identified in ALL post–allo-SCT relapses in our
study affect the DNA-binding domain. As it was previously reported
that ALL samples harboring this type of mutation are sensitive to
the small molecule APR-246, we performed drug sensitivity tests
and could indeed show efficient targeting of leukemic blasts by
this compound. Moreover, as TP53 mutations indicate tumor
escape, and thus resistance to conventional chemotherapy, our
findings point to a high demand for novel therapeutic targets in the
setting of post–allo-SCT relapses.
The clinically most relevant finding was that in 9 of 10 children, we
identified alterations in genes for which additional nonstandard
therapies with approved drugs are available. This proportion was
substantially higher than the recently published data from the
INFORM pilot study, in which, although based on the same list of
alterations and matched novel agents, a potentially druggable
alteration was only detected in 50% of children.36
Five patients displayed NRAS/KRAS mutations, which were all
in known hotspot positions (AA12/13/61). The MEK inhibitor
Trametinib represents a promising therapeutic option in RAS
mutated tumors and has already been used successfully in refractory
myeloid malignancies.54,55 In addition, KRASmutations were recently
shown to be highly sensitive to the MEK inhibitor Selumetinib in
mice xenografted with primary pediatric ALL blasts carrying the
AA12 hotspot mutant,56 thus providing in vivo validation for this
therapeutic target.
A previous study reported a mean of 0.5 mutations per megabase in
ALL.57 Looking specifically at the few much larger oncogenomes in
our study, newly acquired somatic SNVs were indeed found in DNA
polymerases and DNA repair/Fanconi anemia genes in all cases. As
mutational burden has recently emerged as a promising biomarker
for clinical response to various immunotherapies, immune check-
point inhibition58 represents another individualized therapeutic
option for those patients with high mutational burden in the
post–allo-SCT relapses.
Although the exact threshold for a hypermutator phenotype in
pediatric ALL remains to be defined, 1 recent pan-pediatric
cancer paper defined it as at least 2 coding mutations per MB
(“pediatric high” in contrast to the adult “hypermutated” of at
least 10 coding mutations per MB),13 whereas a second publica-
tion, which analyzed a larger number of pediatric lymphoblastic
leukemias, defined it as at least 0.4 somatic mutations per MB
(B-ALL) and at least 0.8 somatic mutations per MB (T-ALL),
respectively.14 All large oncogenomes identified in our study are
well above these thresholds.
As we had only leukemic DNA available, we were not able to
analyze whether pathways that may influence immune function
(such as the downregulation of MHC class II genes) were also
affected in the post–allo-SCT setting, although on the DNA level,
we did we did not identify any deletions spanning more than 1 of
the following genetic loci: HLA-A, HLA-B, HLA-C, HLA-DPB1,
HLA-DQB1, HLA-DRB1 (data not shown). Such dysregulations
were recently shown in 50% of adult patients relapsing with
AML after allo-SCT.59
Taken together, our study is the first to identify RAS pathway
mutations, TP53 alterations, and hypermutator phenotypes as
recurrent and potentially druggable genetic lesions in post–allo-
SCT relapses. At the same time, mutational cluster analysis reveals
highly dynamic clonal composition regarding both cancer-related
and bystander mutations in individual patients over time, thus
providing a cautionary note on leukemia escape to individu-
alized therapies that rely on single-target approaches. Ther-
apeutic targets identified in post–allo-SCT relapses are well
amenable to combinatorial approaches, as they display nonover-
lapping toxicities and hold promise to complement innovative
approaches as CAR T-cell immunotherapy and bispecific T-cell
engagers.
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